Plain-English translation of NCT05141058 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a treatment called donor-derived CSTs (cytotoxic T cells) to help prevent COVID-19 infection in people whose immune systems are weakened after a stem cell transplant. The medication consists of specially grown immune cells from the person's transplant donor that are designed to recognize and fight COVID-19. Researchers are testing three different doses to find the safest and most effective level.
People who have received a stem cell transplant have very weak immune systems for months afterward, making them extremely vulnerable to serious COVID-19 infection. Current prevention methods (like vaccines) don't work well in these patients, so researchers are exploring whether donor immune cells can provide direct protection instead.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive one infusion of immune cells grown from your transplant donor's blood cells. You'll be monitored closely for at least 45 days afterward with blood tests and health check-ins to watch for any side effects and to see if the cells help protect you from COVID-19. The study is enrolling adults first, then older children, then younger children, with each group starting at lower doses to ensure safety before moving to higher doses.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States